Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.9MCash, Jul 2026
7moCash Runway (est.)
+94%Share Count, 1 Year
Follow BTTC by emailGet an email when BTTC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BTTC, unsubscribe in one click. Privacy
📣 What BTTC Says Is Next
H2 2026 · “Issuance remains contingent on the consortium’s Electronic Money Institution licence, still pending before De Nederlandsche Bank, with commercial launch targeted for H2 2026.”
Company press release, Sep 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Shareholder vote Black Titan reminds shareholders to vote at its 2026 Annual and Extraordinary General Meeting, to be held virtually on Monday, November 16, 2026, at 9:00 a.m. Eastern time. Form 6-K · SEC filing
Nov 6, 2026 ·
Annual report for the period ended Jul 31, 2026 Form 20-F · SEC filing
Oct 13, 2026 ·
Shareholder vote Black Titan Corporation filed notice of a November 16, 2026 virtual annual and extraordinary general meeting. Shareholders will vote on an 11:1 share consolidation, a resulting increase in authorised share capital to US$11,050,000, new articles, four directors, and ratification of Guangdong Prouden CPAs GP. Form 6-K · SEC filing · Press release
Sep 18, 2026 ·
Black Titan published a press release analyzing stablecoin and DeFi developments, including Compound's institutional USDC market with up to 200,000 USDC in supplier incentives and Coinbase's Morpho-powered Brazil lending rollout. The company itself reported no financing, deal or results. Form 6-K · SEC filing · Press release
Sep 4, 2026 ·
Listing Black Titan received a Nasdaq notice on September 2, 2026 that its shares closed below the $1.00 minimum bid price for 30 consecutive business days. It has until March 1, 2027 to regain compliance, with a possible additional 180-day period. Form 6-K · SEC filing · Press release
Sep 2, 2026 ·
Financing Black Titan reported that its senior unsecured convertible note, issued January 16, 2026 at a $1,515,000 principal, was fully converted into 2,924,082 ordinary shares between May and August 20, 2026, with no amounts remaining outstanding. Form 6-K · SEC filing · Press release
Aug 19, 2026 ·
Black Titan issued a press release analyzing stablecoin payments: USDC circulation grew 19% year over year to $73.3 billion, quarterly onchain volume rose 151% to $14.8 trillion, and CPN reached $14.7 billion annualized volume. Form 6-K · SEC filing · Press release
Aug 14, 2026 ·
Black Titan issued a research note on DeFi and lending infrastructure, citing Uniswap's July 31, 2026 "Earn" feature built on Morpho, Bitget's integration of 125 million users into MetaMorpho vaults, and Morpho's July 29 deployment on HashKey's HSK Chain. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · N/A · Upcoming Trial · Black Forest Cocoa Flavanol Supplementation and Health Trial Registry primary completion date, not a results date
Nov 2028 · Phase 2 · Recruiting · Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Registry primary completion date, not a results date
Jun 2030 · Phase 1/2 · Enrolling · Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF… Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BTTC's own candidates): Temozolomide, Azathioprine, Carfilzomib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BTTC reported $2.9M in cash and short-term investments (as of Jul 31, 2026) and used about $1.3M/quarter in operations, an estimated runway of 6.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:73 · High
Cash runway 7 months +30
S-1 registration (Feb 2026) +8
Going-concern doubt in the latest 20-F +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern.20-F, Nov 2026
Share count 14,996,962 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BTTC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BTTC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.